S&P 500   4,207.53 (+0.05%)
DOW   33,036.59 (-0.17%)
QQQ   350.24 (+0.53%)
AAPL   177.48 (+1.17%)
MSFT   332.28 (-0.18%)
META   262.71 (+0.26%)
GOOGL   123.84 (-0.62%)
AMZN   121.77 (+1.38%)
TSLA   201.13 (+4.12%)
NVDA   400.04 (+2.72%)
NIO   7.45 (-3.25%)
BABA   78.66 (-2.85%)
AMD   125.38 (-1.30%)
T   15.64 (+0.90%)
F   12.63 (+4.47%)
MU   72.16 (-2.39%)
CGC   0.85 (-3.11%)
GE   102.18 (-0.55%)
DIS   87.62 (-0.76%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   62.05 (+3.04%)
NFLX   393.09 (+3.75%)
S&P 500   4,207.53 (+0.05%)
DOW   33,036.59 (-0.17%)
QQQ   350.24 (+0.53%)
AAPL   177.48 (+1.17%)
MSFT   332.28 (-0.18%)
META   262.71 (+0.26%)
GOOGL   123.84 (-0.62%)
AMZN   121.77 (+1.38%)
TSLA   201.13 (+4.12%)
NVDA   400.04 (+2.72%)
NIO   7.45 (-3.25%)
BABA   78.66 (-2.85%)
AMD   125.38 (-1.30%)
T   15.64 (+0.90%)
F   12.63 (+4.47%)
MU   72.16 (-2.39%)
CGC   0.85 (-3.11%)
GE   102.18 (-0.55%)
DIS   87.62 (-0.76%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   62.05 (+3.04%)
NFLX   393.09 (+3.75%)
S&P 500   4,207.53 (+0.05%)
DOW   33,036.59 (-0.17%)
QQQ   350.24 (+0.53%)
AAPL   177.48 (+1.17%)
MSFT   332.28 (-0.18%)
META   262.71 (+0.26%)
GOOGL   123.84 (-0.62%)
AMZN   121.77 (+1.38%)
TSLA   201.13 (+4.12%)
NVDA   400.04 (+2.72%)
NIO   7.45 (-3.25%)
BABA   78.66 (-2.85%)
AMD   125.38 (-1.30%)
T   15.64 (+0.90%)
F   12.63 (+4.47%)
MU   72.16 (-2.39%)
CGC   0.85 (-3.11%)
GE   102.18 (-0.55%)
DIS   87.62 (-0.76%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   62.05 (+3.04%)
NFLX   393.09 (+3.75%)
S&P 500   4,207.53 (+0.05%)
DOW   33,036.59 (-0.17%)
QQQ   350.24 (+0.53%)
AAPL   177.48 (+1.17%)
MSFT   332.28 (-0.18%)
META   262.71 (+0.26%)
GOOGL   123.84 (-0.62%)
AMZN   121.77 (+1.38%)
TSLA   201.13 (+4.12%)
NVDA   400.04 (+2.72%)
NIO   7.45 (-3.25%)
BABA   78.66 (-2.85%)
AMD   125.38 (-1.30%)
T   15.64 (+0.90%)
F   12.63 (+4.47%)
MU   72.16 (-2.39%)
CGC   0.85 (-3.11%)
GE   102.18 (-0.55%)
DIS   87.62 (-0.76%)
AMC   4.61 (-0.65%)
PFE   37.03 (-1.52%)
PYPL   62.05 (+3.04%)
NFLX   393.09 (+3.75%)
NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Forecast, Price & News

$6.23
-0.05 (-0.80%)
(As of 03:37 PM ET)
Compare
Today's Range
$6.02
$6.43
50-Day Range
$4.38
$9.93
52-Week Range
$2.00
$10.30
Volume
149,268 shs
Average Volume
154,593 shs
Market Capitalization
$112.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
197.0% Upside
$18.50 Price Target
Short Interest
Bearish
3.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Achieve Life Sciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.59) to ($1.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

795th out of 1,009 stocks

Diagnostic Substances Industry

9th out of 16 stocks


ACHV stock logo

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Stock News Headlines

ACHV: ORCA-3 Topline
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser
Small cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>
ACHV: First Quarter Results
Q1 2023 Achieve Life Sciences Inc Earnings Call
ACHV: ORCA-V1 Readout
See More Headlines
Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Company Calendar

Last Earnings
3/16/2023
Today
5/30/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHV
CUSIP
68230A10
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+194.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-42,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.46 per share

Miscellaneous

Free Float
17,861,000
Market Cap
$113.29 million
Optionable
Not Optionable
Beta
1.52

Key Executives

  • John A. BencichJohn A. Bencich
    Director, Chief Executive & Financial Officer
  • Cindy A. Jacobs
    President, Chief Medical Officer & Director
  • Anthony John Clarke
    Chief Scientific Officer
  • Jaime Xinos
    Executive Vice President-Commercial
  • Jerry Wan
    Principal Accounting Officer













ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings
or view top-rated stocks.

What is Achieve Life Sciences' stock price forecast for 2023?

2 equities research analysts have issued 12 month target prices for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 194.6% from the stock's current price.
View analysts price targets for ACHV
or view top-rated stocks among Wall Street analysts.

How have ACHV shares performed in 2023?

Achieve Life Sciences' stock was trading at $2.45 on January 1st, 2023. Since then, ACHV stock has increased by 156.3% and is now trading at $6.28.
View the best growth stocks for 2023 here
.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 633,200 shares, an increase of 11.2% from the April 30th total of 569,600 shares. Based on an average trading volume of 156,300 shares, the short-interest ratio is presently 4.1 days.
View Achieve Life Sciences' Short Interest
.

When is Achieve Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACHV earnings forecast
.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.07. During the same quarter in the previous year, the company earned ($0.76) earnings per share.

When did Achieve Life Sciences' stock split?

Achieve Life Sciences shares reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.00%), LPL Financial LLC (0.80%), Long Focus Capital Management LLC (0.78%), Perkins Capital Management Inc. (0.77%), Raymond James & Associates (0.58%) and Susquehanna International Group LLP (0.00%).
View institutional ownership trends
.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $6.28.

How much money does Achieve Life Sciences make?

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $113.29 million. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -